Meet the Expert sessions are an opportunity for delegates to sit down and converse on a more one-to-one level with the experts in their field.
Please note that Meet the Expert sessions are not included in the general Meeting registration fee, and must be purchased separately. The fee is €30 (VAT included) per session. Tickets are available on a first-come, first-served basis.
For the first time this year, supporting companies provide additional Meet the Expert sessions. Pre-registration is required via the general registration form. For further information, please check our Industry Meet the Expert lunch sessions here.
Saturday, 29 August
| CODE | TOPIC | EXPERT |
|---|---|---|
| MTE-1 | Viral infections in HSCT recipients: the challenges in 2020 | Francisco Marty (US) |
| MTE-2 | Extracorporeal Photopheresis in the Management of Acute and Chronic GvHD | Daniel Couriel (US) |
| MTE-3 | The role of donor registries in the changing landscape of allogeneic HSCT in 2020 | TBC |
| MTE-4 | How to manage chronic GvHD in 2020 and beyond | Steven Pavletic (US) |
| MTE-5 | The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020? | Sergi Querol (SP) |
| MTE-6 | How to establish a CAR T Cell Delivery Centre | Claire Roddie (UK) |
| MTE-7 | How to manage Acute Promyelocytic Leukemia in 2020. Current role of Hematopoietic Cell Transplantation | Miguel Ángel Sanz (SP) |
Sunday, 30 August
| CODE | topic | expert |
|---|---|---|
| MTE-8 | HSCT in high-risk MDS | David Valcárcel (SP) |
| MTE-9 | Prophylaxis of acute graft versus host disease: ATG or not ATG? | Francesca Bonifazi (IT) |
| MTE-10 |
Clinical Hurdles for Academic Development of Clinical Advanced Therapies: the perspective from the GMP Lab |
Fermín Sánchez-Guijo (SP) |
| MTE-11 | The fast changing paradigm of myeloma treatment: what's best in 2020? | Sergio Giralt (US) |
| MTE-12 | How I manage double hit lymphomas | Andrew Davies (UK) |
| MTE-13 | The role of HSCT in Mantle Cell Lymphoma in 2020 | Olivier Hermine (FR) |
| MTE-14 | Maintenance strategies after allogeneic HSCT in patients with AML | Ali Bazarbachi (LB) |
Monday, 31 August
| code | topic | expert |
|---|---|---|
| MTE-15 | Fungal infections in HSCT recipients - the challenges in 2020 | Livio Pagano (IT) |
| MTE-16 | HSCT and gene therapy in inherited metabolic diseases | Robert Wynn (UK) |
| MTE-17 | Current challenges facing emerging donor registries in 2020 | Mahmoud Aljurf (SA) |
| MTE-18 | HSCT indications in paediatric MDS | Charlotte Niemeyer (DE) |
| MTE-19 | Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020 | Stephan Mielke (SE) |
| MTE-20 | Current role of mesenchymal stromal cells in HSCT | Peter Bader (DE) |
| MTE-21 |
HSCT in MS and immune-mediated neurological diseases: patient selection and follow-up |
Basil Sharrack (UK) |